Trial Profile
A Phase 1b Open-Label, Proof of Concept Study to Evaluate the Safety and Efficacy of Novel Hepatitis B Virus (HBV) Combination Therapies in Chronic Hepatitis B (CHB) Subjects
Status:
Not yet recruiting
Phase of Trial:
Phase I
Latest Information Update: 19 Nov 2018
Price :
$35
*
At a glance
- Drugs Ledipasvir/sofosbuvir (Primary) ; Nivolumab (Primary) ; Selgantolimod (Primary)
- Indications Hepatitis B
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Gilead Sciences
- 19 Nov 2018 New trial record